Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immunotherapy

Involuted TLS as a harbinger of HCC regression

Nature Immunology volume 25, pages 1986–1987 (2024)Cite this article

Subjects

Tertiary lymphoid structures (TLS) have different stages and cellular compositions in human tumors. New data are showing the effect of neoadjuvant immunotherapy on the fate of TLS in treatment-responsive versus treatment-resistant liver cancers.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Involuted TLS develop in regressed tumor beds after effective immunotherapy.

References

  1. Teillaud, J. L., Houel, A., Panouillot, M., Riffard, C. & Dieu-Nosjean, M. C. Nat. Rev. Cancer. 24, 629–646 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. Schumacher, T. N. & Thommen, D. S. Science 375, eabf9419 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Shu, D. H. et al. Nat. Immunol. https://doi.org/10.1038/s41590-024-01992-w (2024).

    Article  PubMed  Google Scholar 

  4. Calderaro, J. et al. J. Hepatol. 70, 58–65 (2019).

    Article  PubMed  Google Scholar 

  5. Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Nat. Rev. Cancer. 19, 307–325 (2019).

    Article  PubMed  Google Scholar 

  6. Ishigami, E. et al. Breast Cancer 26, 180–189 (2019).

    Article  PubMed  Google Scholar 

  7. Chelvanambi, M., Fecek, R. J., Taylor, J. L. & Storkus, W. J. J. Immunother. Cancer 9, e001906 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  8. van Hooren, L. et al. Nat. Commun. 12, 4127 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bod, L. et al. Nature 619, 348–356 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Finkin, S. et al. Nat. Immunol. 16, 1235–1244 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yang, Y. et al. Cell 187, 4790–4811 (2024).

    Article  CAS  PubMed  Google Scholar 

  12. Zhang, Y. et al. Cancer Cell 42, 1370–1385 (2024).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Xin Liu & Dan G. Duda

  2. Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    Xin Liu

Authors
  1. Xin Liu
    View author publications

    Search author on:PubMed Google Scholar

  2. Dan G. Duda
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Dan G. Duda.

Ethics declarations

Competing interests

D.G.D. declares research grants from Bayer, Exelixis, Surface Oncology, and Bristol Myers Squibb. X.L. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Duda, D.G. Involuted TLS as a harbinger of HCC regression. Nat Immunol 25, 1986–1987 (2024). https://doi.org/10.1038/s41590-024-01990-y

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41590-024-01990-y

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer